Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Chantix Launch Priority Is Managing Expectations, McKinnell Says

Executive Summary

Managing expectations about the effectiveness of Pfizer's smoking cessation therapy Chantix at launch will be vital to the long-term success of the compound, CEO Hank McKinnell said

You may also be interested in...



Alli Approved OTC For Weight Loss With “Goal Oriented” Indication

FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed

Pfizer Continues Slow Exubera Roll-Out, Wants To Grow Chantix Market

Exubera goes to primary care in 2007: Pfizer will roll out its inhaled insulin Exubera to general practitioners starting in January, the company said; patient and physician education programs limited to endocrinologists began in July (1"The Pink Sheet" July 24, 2006, p. 3). Compensation for sales reps will also change in January: Reps "were incentivized to educate rather than drive volume," Pfizer Head of U.S. Pharmaceutical Operations Peter Brandt said Oct. 19 during the firm's third quarter earnings call. "We are going to be driving more of the volume out of the next wave of our rollout going to the GP community"...

McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale

Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said

Related Content

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel